Please	hne a	atus sign	(+)) inside	this b	ΩX	_
riease	IANG G	UIUS SIIII I	т.	1113100	4430	~	

	O 1 P. S. MAR 25 2004	JC24
1	PADEMARY OF	

Substitute for form 1449A/B/PTO

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2 Sheet

Complete if Known				
Application Number	10/644,530			
Filing Date	August 20, 2003			
First Named Inventor	ROBERTS, Alan			
Group Art Unit	1614			
Examiner Name	SPIVACK			
Attomey Docket Number	220551			

	U.S. Patent Do	cument			
Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
AA	6,407,128		Scaife et al.	Jun. 18, 2002	
AB	6,455,557	1	Pellegrini et al.	Sep. 24, 2002	
	l				· · · · · · · · · · · · · · · · · · ·
	No.	Doc. Application or Patent Number A A 6,407,128	No. Patent Number Kind Code AA 6,407,128	Doc. No. Application or Patent Number Kind Code Name of Patentee or Applicant AA 6,407,128 Scaife et al.	Doc. No. Application or Patent Number Kind Code Name of Patentee or Applicant Date of Publication AA 6,407,128 Scaife et al. Jun. 18, 2002

		F	oreign Patent Docume	nt	•		Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
75	AC	wo	01/08681	A1	First Horizon Pharmaceutical Corp.	Feb. 8, 2001		

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Trans Yes	No*+
P5	AD.	Ali-Melkkila et al, "Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings," Acta Anaesthesiol. Scand., 33: 513-517 (1989).		
PS	AE	Ali-Melkkila et al., "Pharmacokinetics and related pharmacodynamics of anticholinergic drugs," <i>Acta Anasthesiol. Scand.</i> , 37: 633-642 (1993).		
15	AF	Chen, "Troglitazone: An antidiabetic agent," Am J. of Health-Syst. Pharm., 55: 905-925 (1998).	,	
PS	AG	Evans, "Influence of Dietary Components on the Gastrointestinal Metabolism and Transport of Drugs," <i>Therapeutic Drug Monitoring</i> , 22: 131-136 (2000).		
75	AH	Greene et al., "Clinical Pharmacokinetics of Nefazodone," Clin. Pharmacokinet., 33(4): 260-275 (1997).		<u> </u>
P5	ΑI	Gillen et al., "Problems related to acid rebound and tachyphylaxis," Best Pract. & Res. Clin. Gastroenterology, 15(3): 487 495 (2001).		
PS	AJ	Kirk, "Significant Drug-Nutrient Interactions," Amer. Fam. Phys., 51(5): 1175-1182 (1995).		
23	AK	Loi et al., "Clinical Pharmacokinetics of Troglitazaone," Clin. Pharmacokinet., 37(2):91-104 (1999).		
125	AL	Martinez et al., "A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals," <i>J. Clin. Pharmacol.</i> , 42: 620-643 (2002).		
1/5	AM	Pelkonen et al., "In vitro prediction of gastrointestinal absorption and bioavailability: and experts' meeting report," Eur. J. Clin. Pharmacol., 57: 621-629 (2001).		
75	AN	Rautakorpi et al., "Pharmacokinetics and Oral Bioavailability of Glycopryrrolate in Children," <i>Pharmacology & Toxicology</i> , 83: 132-134 (1998).		

Date Considered

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	 2

Complete if Known				
Application Number	10/644,530			
Filing Date	August 20, 2003			
First Named Inventor	ROBERTS, Alan			
Group Art Unit	1614			
Examiner Name	· SPINALE			
Attorney Docket Number	220551			

B	AO	Rautakorpi et al., "Pharmacokinetics of Glycopyrrolate in Children," J. Clin. Anesth., 6: 217-220 (1994).		
1 PS	AP	Singh, "Effects of Food on Clinical Pharmacokinetics," Clin. Pharmacokinet., 37(3): 213-255 (1999).		
75	AQ	Temple et al., "Rifapentine: Its Role in the Treatment of Tuberculosis," The Annals of Pharmacotherapy, 33: 1203-1210 (1999).		
75	AR	Toothaker et al., "The Effect of Food on Drug Bioavailability," Ann. Rev. Pharmacol. Toxicol., 20: 173-199 (1980).		
B	AS	van Leerdam et al. "The role of acid suppressants in upper gastrointestinal ulcer bleeding," Best Pract. & Res. Clin. Gastroenterology, 15(3): 463-475 (2001).		
PS	AT	Walter-Sack et al., "Influence of Diet and Nutritional Status on Drug Metabolism," Clin. Pharmacokinet., 31(1): 47-64 (1996).		
P5	ΑU	Welling, "Interactions Affecting Drug Absorption," Clin. Pharmacokinet., 9: 404-434 (1984).		
				
			\vdash	
				-
	<u> </u>			
	 			
	 			
	-:			
	 			_
	 		 	
		·	\vdash	
	 		 	
<u> </u>		· · · · · · · · · · · · · · · · · · ·		

Examiner Signature

Date Considered

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).